How The University of Manchester is contributing to the fight against coronavirus
At The University of Manchester, our people are working together and with partners from across society to understand coronavirus (COVID-19) and its wide-ranging impacts on our lives.
Researchers, teachers, students and professional service staff are combining their knowledge to contribute to the local, national and international response to the disease.
Using maths to combat coronavirus
Manchester mathematicians are using their computer modelling expertise to advise the government on how to best protect the UK population.
UK coronavirus support for self-employed “generous”
Professor Jill Rubery comments that the UK's support for self-employed during COVID-19 is "generous" by global standards.
Supporting youth mental health during COVID-19
Use online support networks to provide continuity and improve wellbeing during school closures, says Manchester academic.
Creating a national picture of COVID-19 symptoms
Manchester statisticians are analysing data from a new heat map of public health information to support response planning.
Working with Greater Manchester to accelerate trials
University scientists and regional partners are helping in a national effort to accelerate clinical trials in intensive and critical care patients.
Transforming human genomic testing labs
A genetic testing team are adapting lab space to accelerate testing in the north-west.
Protecting homeworkers from cyber crime
Manchester experts explain the steps we can take to guard against cyber crime while working from home.
Dealing with COVID-19 in the global south
Professor Diana Mitlin discusses how the transition of COVID-19 is increased, and strategies to tackle it are more difficult, in informal urban settlements.
Research to address the pandemic
We’ve established a COVID-19 research rapid response group through which scientists in our Faculty of Biology, Medicine and Health are working with NHS colleagues from Manchester University NHS Foundation Trust and the Northern Care Alliance NHS Group, supported by Health Innovation Manchester, and utilising our experimental and translational research expertise through the NHIR Manchester Biomedical Research Centre and NIHR Manchester Clinical Research Facility.
This brings together the research and innovation strengths of our partnerships in an unprecedented way to focus on this public health crisis. Our aims are to minimise lives lost nationally and globally, and reduce the impact of the pandemic on Greater Manchester’s health and social care system and the wider community.
The group’s work is focusing on a number of key priorities:
We will play a full part in the leadership, coordination and execution of clinical trials. These are focused on new therapies aimed at improving clinical outcomes and are employing a range of therapies including antivirals, anti-inflammatory agents and other novel intensive care modalities.
Our partnership is seeking opportunities to fund additional new trials and we are developing protocols in Greater Manchester for new therapies, informed by our previous research in other contexts where a 'hyper-immune' response has been observed.
Our world-leading virology and inflammation/immunology teams, including members of our Lydia Becker Institute of Immunology and Inflammation, are working actively to study patients in real-time in order to better understand the mechanisms by which this virus causes severe reactions particularly in the lungs. Such work will suggest new treatment approaches which we can then test.
Our expertise in data science, mathematics and computer modelling is being harnessed to help identify and track patients with symptoms to identify those who are deteriorating and who need more intensive interventions at an earlier stage.
This collaboration, between the University and NHS trusts, will use routinely collected patient data updated throughout the day to allow early escalation of patients to more active treatment.
Our public health and applied health researchers are working on developing and evaluating ways to relieve the pressure that the NHS and social care systems. Such work requires close cooperation between the local authorities, public health teams and the NHS.
Our leadership in this area will enable evaluation of any new approaches from which we can draw lessons for future outbreaks and more efficient deployment of health and social care facilities.
Many patients with pre-existing diseases who are on treatments that suppress their immune systems are particularly vulnerable to the more severe complications of COVID-19. Our researchers are leading on European and global efforts to track these patients.
By doing so we will be able to provide more person-centred advice about management of their background condition and treatment during such outbreaks.
Our partnership is working closely with major industry partners to develop and deploy rapid diagnosis testing platforms to scale up for mass, widespread testing during this acute outbreak.
We are in discussions with manufacturers who are developing vaccines to prevent COVID-19. The Greater Manchester partnership has experience of deploying clinical trials at large scale within the community – for example, the recent Salford Lung Study. This approach and population-based tracking of patients will help support rapid recruitment and read out of results for any future vaccination trials so that these vaccines can be in use as soon as possible.
Meanwhile, many of our colleagues have been offering their services away from their own core University roles towards supporting coronavirus research and also helping the NHS on the ground.
Read the latest news for staff and current and prospective students.
Expert media group
View our list of scientists and academics who are able to provide insights on a range of aspects of the COVID-19 outbreak.